Abstract 267P
Background
We investigated the landscape of clinically relevant mutations in ctDNA from NSCLC patients in India tested by a commercially available comprehensive next generation sequencing (NGS) assay (Guardant360®) as part of clinical practice.
Methods
Test requests from patients with a diagnosis of advanced stage “lung cancer” were reviewed. We then excluded cases with neuroendocrine (including small cell), sarcomatoid, and pure squamous histology. Clinically relevant biomarkers were defined as mutations in EGFR, ERBB2, KRAS, BRAF V600E, MET exon 14 skipping or amplification; and ALK, ROS1, RET, or NTRK1 rearrangements. Synonymous mutations and variants of unknown significance were excluded.
Results
Among 120 samples from advanced non-squamous NSCLC patients, 47 were from women and 73 from men; median patient age was 66 years. The median turnaround time was 6 days from sample receipt in laboratory to report. Tumour DNA was detected in 112 samples (93.4%), and among these 57 (50.9%) had at least one clinically relevant biomarker. Mutations in EGFR were the most common (n=32, 28.6%) and included exon 19 deletion (n=19, 60.8%), L858R (n=5, 16%), exon 18 deletion (n=1, 3.2%), exon 20 insertion (n=4, 12.8%), and other pathogenic point mutations (n=6, 19.2%). Compound EGFR mutations occurred in 10 samples, including 4 with a driver mutation and T790M. Other biomarkers included mutations in KRAS (n=4, 3.6%) and ERBB2 (n= 11, 9.8%), rearrangements of ALK (n=2, 1.8%), RET (n=3, 2.7%), MET exon 14 skipping (n=5, 4.5%), and MET focal amplification (n=1, 0.9%). Among 89 samples that lacked commonly tested alterations (EGFR exon 19 deletion, EGFR L858R, ALK fusion or ROS1 fusion), clinically informative alterations were detected in 34 (38.2%). Table: 267P
Summary of alterations detected in advanced NSCLC patients
Genes altered | Frequency (N=120) |
EGFR | 28.6% |
ERBB2 | 9.8% |
KRAS | 3.6% |
MET | 5% |
ALK | 1.8% |
ROS1 | 0% |
RET | 2.7% |
Conclusions
Clinically relevant biomarkers were detected in more than half of plasma samples from Indian advanced non-squamous NSCLC patients tested with plasma based NGS. Using a single assay, both common and rare mutations could be found in a timely manner (median 6 days turnaround time), obviating the need for multiple tests to identify less common actionable alterations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guardant Health AMEA.
Funding
Has not received any funding.
Disclosure
A.K. Mukherjee, N. Joshi, S. Olsen: Financial Interests, Institutional, Full or part-time Employment: Guardant Health Inc. All other authors have declared no conflicts of interest.
Resources from the same session
246P - Clinicoepidemiological profile and patterns of failure in carcinoma oral cavity in Indian patients: A 6-year retrospective study
Presenter: Aashita -
Session: Poster viewing 03
247TiP - Addition of induction, concurrent and maintenance durvalumab to induction and concurrent chemoradiation vs induction and concurrent chemoradiation for previously untreated locoregionally advanced nasopharyngeal carcinoma: A phase II randomised-controlled trial
Presenter: Victor Lee
Session: Poster viewing 03
248P - The use of complementary medicine in Chinese pediatric patients receiving palliative care: A multi-centre study
Presenter: Chun SIng Lam
Session: Poster viewing 03
249P - Improving quality of life and symptom burden with opioids and adjuncts in lung cancer (IQSOL study)
Presenter: Naren Gokulanathan
Session: Poster viewing 03
250P - An analysis of nutritional and psychological status of patients with advanced cancer
Presenter: Shasha Wang
Session: Poster viewing 03
251P - Is QUAD SHOT palliative cyclical hypo-fractionated radiotherapy in advanced head and neck cancer the way to go? An alternative regimen in low resource countries
Presenter: Ravi Kanodia
Session: Poster viewing 03
252P - Preferred place of death among terminally ill cancer patients: A single centre observational study from India
Presenter: Suhana Sulfiker
Session: Poster viewing 03
253P - Hemostatic radiotherapy for gastric cancer: MRI as an alternative to endoscopy for post-treatment evaluation
Presenter: Osamu Tanaka
Session: Poster viewing 03
254P - Sexual function of cervical cancer survivors: A single center prospective study
Presenter: Dinesh Ravikumar
Session: Poster viewing 03
255P - Volunteers’ role to provide quality palliative care for terminal cancer
Presenter: SAPTAPARNA JANA
Session: Poster viewing 03